MCID: BRN012
MIFTS: 55

Bronchiolitis Obliterans

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchiolitis Obliterans

MalaCards integrated aliases for Bronchiolitis Obliterans:

Name: Bronchiolitis Obliterans 12 52 54 43 15 37 17 71
Obliterative Bronchiolitis 12 52 36
Bronchiolitis Fibrosa Obliterans 12 71
Bronchiolitis, Exudative 71
Bronchiolitis Exudativa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2799
KEGG 36 H01873
MeSH 43 D001989
NCIt 49 C62580
SNOMED-CT 67 40100001
UMLS 71 C0006272 C2350876 C3241980

Summaries for Bronchiolitis Obliterans

KEGG : 36 Obliterative bronchiolitis (OB), also known as bronchiolitis obliterans, is a rare but serious condition resulting in progressive and irreversible airway obstruction. This disease is the result of injury to the respiratory and terminal bronchioles from a wide variety of potential causes. Although the pathogenesis of OB remains poorly understood, it seems clear that a multifaceted process of inflammation and resultant fibrotic transition occurs, resulting in airflow limitation and development of disease. Although OB has been described in all age groups, the frequency of underlying causes and potential prognoses are different for children and adults. For example, OB in children is most often seen following a severe lower-respiratory-tract infection, usually of adenovirus, whereas OB in adults is more commonly associated with occupational inhalation injuries, hypersensitivity pneumonitis, and autoimmune disorders. In lung transplant recipients, bronchiolitis obliterans syndrome is the major cause of death after the first year of transplantation and is a form of allograft rejection. There is no uniformly accepted treatment protocol for patients with OB. Many patients are tried on corticosteroids or other immunosuppressants based on anecdotal evidence of improvement. However, these medications have significant toxicity.

MalaCards based summary : Bronchiolitis Obliterans, also known as obliterative bronchiolitis, is related to cryptogenic organizing pneumonia and graft-versus-host disease. An important gene associated with Bronchiolitis Obliterans is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Macitentan and Erythromycin have been mentioned in the context of this disorder. Affiliated tissues include Lung, heart and bone, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology : 12 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults.

NIH Rare Diseases : 52 Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation . While there is no way to reverse the disease, treatments are available that may stabilize or slow the progression. Another similarly named disease, bronchiolitis obliterans organizing pneumonia , is a completely different disease.

Wikipedia : 74 Obliterative bronchiolitis (OB), also known as constrictive bronchiolitis and popcorn lung, is a disease... more...

Related Diseases for Bronchiolitis Obliterans

Diseases related to Bronchiolitis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 821)
# Related Disease Score Top Affiliating Genes
1 cryptogenic organizing pneumonia 34.1 TNF TIMP1 SFTPD MMP9 CXCL8 CRP
2 graft-versus-host disease 32.0 TNF IL6 IL10 IFNG
3 chronic graft versus host disease 31.9 IL10 IFNG
4 bronchiolitis 31.5 TNF SFTPD SCGB1A1 IL6 IL17A IL13
5 pneumothorax 31.4 TIMP1 MMP9 CRP
6 cytomegalovirus infection 31.4 TNF IL6 CXCL8
7 acute graft versus host disease 31.4 TNF IL10 IFNG
8 bronchiectasis 31.3 TNF SLPI MPO MMP8 CXCL8 CRP
9 measles 31.2 TNF IL6 IFNG CXCL8
10 eosinophilic pneumonia 31.1 SFTPD IL6 IL13 CXCL8
11 pemphigus 31.1 TNF PPL IL6 IL10 EVPL
12 gastroesophageal reflux 31.0 TNF MPO IL6 FOXP3 CXCL8
13 rheumatoid arthritis interstitial lung disease 30.9 TNF SFTPD CRP
14 erythema multiforme 30.8 TNF IL6 IL13 IFNG CXCR3 CXCL8
15 peptic esophagitis 30.8 TNF IL6 CXCL8
16 cryoglobulinemia 30.8 TNF IL6 IL10 IFNG
17 mixed connective tissue disease 30.8 TNF IL6 IL10 IFNG
18 crohn's colitis 30.7 TNF IFNG CXCL8
19 ige responsiveness, atopic 30.7 IL13 IL10 IFNG
20 tracheitis 30.7 TNF IL6 CRP
21 invasive aspergillosis 30.7 SFTPD IL10 IFNG CXCL8
22 cold agglutinin disease 30.7 IL6 CRP
23 aspiration pneumonitis 30.7 TNF CXCL8 CRP
24 aspergillosis 30.7 TNF SFTPD IL6 IL10 IFNG CXCL8
25 stevens-johnson syndrome/toxic epidermal necrolysis 30.7 IL13 IFNG CXCR3
26 nocardiosis 30.7 TNF IFNG CRP
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 IL17A IL10 IFNG FOXP3
28 connective tissue disease 30.7 TNF SFTPD IL6 IL17A IL10 IFNG
29 post-transplant lymphoproliferative disease 30.7 TNF IL6 IL10
30 miliary tuberculosis 30.7 TNF IFNG CRP
31 vasculitis 30.7 TNF MPO IL6 IL17A IL10 CRP
32 extrinsic allergic alveolitis 30.7 SFTPD MPO IL6 IL10 CXCR3 CXCL8
33 subacute thyroiditis 30.7 TNF IL6 CRP
34 allergic bronchopulmonary aspergillosis 30.6 SFTPD IL10 IFNG
35 acquired immunodeficiency syndrome 30.6 TNF IL6 IL10 IFNG CRP
36 granulomatosis with polyangiitis 30.6 TNF MPO IL17A CRP
37 pulmonary hypertension 30.6 TNF TIMP1 IL6 IL10 CXCL8 CRP
38 localized scleroderma 30.6 TNF IL6 IL13
39 thyroiditis 30.6 TNF IL6 IL10 FOXP3
40 bronchopneumonia 30.6 TNF MPO IL6 IL10 CXCL8 CRP
41 cryptococcosis 30.6 TNF IL17A IL13 IL10 IFNG
42 neutrophilia, hereditary 30.6 MPO IL6 CRP
43 pustulosis of palm and sole 30.6 TNF IL17A CXCL8 CRP
44 duodenal ulcer 30.5 TNF IL6 IL10 CXCL8
45 adult-onset still's disease 30.5 TNF IL6 CXCL8 CRP
46 plasmodium vivax malaria 30.5 TNF IL6 IL10 IFNG
47 arthropathy 30.5 TNF IL6 IFNG CRP
48 melioidosis 30.5 TNF IL6 IL10 IFNG
49 neuromyelitis optica 30.5 IL6 IL17A CRP
50 polyarteritis nodosa 30.5 MPO IL6 CRP

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans:



Diseases related to Bronchiolitis Obliterans

Symptoms & Phenotypes for Bronchiolitis Obliterans

MGI Mouse Phenotypes related to Bronchiolitis Obliterans:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 CRP CXCR3 FOXP3 IFNG IL10 IL13
2 immune system MP:0005387 10.39 CRP CXCR3 FOXP3 IFNG IL10 IL13
3 hematopoietic system MP:0005397 10.35 CXCR3 FOXP3 IFNG IL10 IL13 IL17A
4 cardiovascular system MP:0005385 10.25 CRP CXCR3 FOXP3 IFNG IL10 IL6
5 mortality/aging MP:0010768 10.24 CXCR3 FOXP3 IFNG IL10 IL13 IL17A
6 integument MP:0010771 10.14 EVPL FOXP3 IFNG IL10 IL13 IL17A
7 digestive/alimentary MP:0005381 10.1 FOXP3 IFNG IL10 IL13 IL17A IL6
8 muscle MP:0005369 9.92 IFNG IL10 IL13 IL6 MMP9 MPO
9 neoplasm MP:0002006 9.91 CXCR3 IFNG IL10 IL6 MMP8 MMP9
10 no phenotypic analysis MP:0003012 9.7 FOXP3 IFNG IL10 IL13 IL17A PDGFB
11 renal/urinary system MP:0005367 9.61 CXCR3 FOXP3 IFNG IL17A IL6 MMP9
12 respiratory system MP:0005388 9.44 CXCR3 FOXP3 IFNG IL10 IL13 IL17A

Drugs & Therapeutics for Bronchiolitis Obliterans

Drugs for Bronchiolitis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Macitentan Approved Phase 4 441798-33-0
2
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
3
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
4
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
5
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7 Endothelin A Receptor Antagonists Phase 4
8 Endothelin Receptor Antagonists Phase 4
9 Parasympatholytics Phase 4
10 Cholinergic Agents Phase 4
11 Albuterol Phase 4
12 Cholinergic Antagonists Phase 4
13 Tiotropium Bromide Phase 4 136310-93-5
14 Bromides Phase 4
15 Tocolytic Agents Phase 4
16 Erythromycin Estolate Phase 4
17 Erythromycin stearate Phase 4
18 Erythromycin Ethylsuccinate Phase 4
19 Gastrointestinal Agents Phase 4
20 Trace Elements Phase 4
21 Olive Phase 4
22 Vitamins Phase 4
23 Nutrients Phase 4
24 Micronutrients Phase 4
25 Calciferol Phase 4
26 lysine Phase 4
27 Vaccines Phase 4
28 Neurotransmitter Agents Phase 4
29 Adrenergic Agents Phase 4
30 Sodium Channel Blockers Phase 4
31 Adrenergic Antagonists Phase 4
32 Sympatholytics Phase 4
33 Anti-Arrhythmia Agents Phase 4
34 Adrenergic beta-Antagonists Phase 4
35 Diuretics, Potassium Sparing Phase 4
36
Clarithromycin Approved Phase 3 81103-11-9 84029
37
Basiliximab Approved, Investigational Phase 3 152923-56-3, 179045-86-4
38
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
39
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
40
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
42
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
43 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
44
Etanercept Approved, Investigational Phase 3 185243-69-0
45
Methoxsalen Approved Phase 3 298-81-7 4114
46
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
47
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
49
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Potential Therapy With MACITENTAN in the Treatment of Chronic Lung Allograft Dysfunction (CLAD) After Lung Transplantation Unknown status NCT02893176 Phase 4 macitentan;placebo (for macitentan)
2 A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01211509 Phase 4 Montelukast
3 Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation Completed NCT01112241 Phase 4 albuterol plus tiotropium
4 Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans Completed NCT00367419 Phase 4 Erythromycin
5 A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01212406 Phase 4 Vitamin D
6 Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation. Completed NCT01009619 Phase 4 Azithromycin;Placebo
7 Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
8 Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Completed NCT00402805 Phase 4
9 A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
10 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
11 Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
12 Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard Completed NCT00381147 Phase 3 Clarithromycin
13 A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
14 A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients Completed NCT00188825 Phase 3 basiliximab
15 Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation Completed NCT00402532 Phase 3 Everolimus;Mycophenolatmofetil
16 A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients Completed NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
17 Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Completed NCT02426112 Phase 3 Azithromycin;Placebo
18 A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation (BMT CTN #0403) Completed NCT00421174 Phase 3 Etanercept;Placebo plus corticosteroid
19 A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2 Recruiting NCT03283007 Phase 3 Nintedanib;Placebo
20 Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts Recruiting NCT02181257 Phase 3
21 A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation Recruiting NCT03657342 Phase 3 Liposomal Cyclosporine A
22 A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation Recruiting NCT03656926 Phase 3 Liposomal Cyclosporine A
23 Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
24 A Phase III, Multicenter Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosprine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single or Double Lung Transplantation Enrolling by invitation NCT04039347 Phase 3 Liposomal Cyclosporine A 5 mg;Liposomal Cyclosporine A 10 mg
25 A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy Terminated NCT01439958 Phase 3 Inhalation
26 CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001 Terminated NCT00938236 Phase 3 Cyclosporine Inhalation Solution (CIS)
27 A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
28 Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients Terminated NCT00930241 Phase 3 Advagraf®;Prograf®
29 Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
30 Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
31 Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
32 Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
33 Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
34 A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
35 Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults Completed NCT00656058 Phase 2 Singulair (Montelukast Sodium)
36 Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Completed NCT01287078 Phase 2 Cyclosporine Inhalation Solution
37 recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
38 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed NCT01273207 Phase 2 Cyclosporine Inhalation Solution (CIS)
39 Aerosol Cyclosporine for Prevention of Lung Rejection Completed NCT00268515 Phase 2 cyclosporine;tacrolimus;prednisone;azathioprine
40 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
41 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study Completed NCT00141726 Phase 2 Etanercept
42 Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation. Completed NCT01952470 Phase 2 Dornase Alfa;Isotonic Saline.
43 Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study - Completed NCT01862965 Phase 2 PredEver
44 An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Recruiting NCT03978637 Phase 1, Phase 2 Itacitinib
45 Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial Recruiting NCT03562416 Phase 2 Nintedanib;Placebo Oral Tablet
46 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial Recruiting NCT03805477 Phase 2 Nintedanib
47 A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT04107675 Phase 2 Liposomal Cyclosporine A;Liposomal Placebo
48 A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Recruiting NCT03674047 Phase 2 ruxolitinib
49 Imaging and Understanding Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation With Hyperpolarized 129Xenon MR Lung Imaging Recruiting NCT03603899 Phase 1, Phase 2 Hp 129Xenon
50 A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 MPH966

Search NIH Clinical Center for Bronchiolitis Obliterans

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchiolitis Obliterans cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchiolitis Obliterans:
Mesenchymal stem cells for obliterative bronchiolitis
Embryonic/Adult Cultured Cells Related to Bronchiolitis Obliterans:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: bronchiolitis obliterans

Genetic Tests for Bronchiolitis Obliterans

Anatomical Context for Bronchiolitis Obliterans

MalaCards organs/tissues related to Bronchiolitis Obliterans:

40
Lung, Heart, Bone, Bone Marrow, T Cells, Breast, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchiolitis Obliterans:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Respiratory Bronchioles Cilliated Cells Affected by disease, potential therapeutic candidate

Publications for Bronchiolitis Obliterans

Articles related to Bronchiolitis Obliterans:

(show top 50) (show all 4276)
# Title Authors PMID Year
1
Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitis. 54 61
20047888 2010
2
Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. 61 54
19632576 2009
3
Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation. 61 54
17613395 2007
4
Bronchoalveolar cellularity and interleukin-8 levels in measles bronchiolitis obliterans. 61 54
17494793 2007
5
Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. 61 54
16741151 2006
6
CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. 61 54
16709871 2006
7
Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients. 54 61
16678030 2006
8
Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. 54 61
15912112 2005
9
Heme oxygenase-1 expression in alveolar macrophages is elevated in patients with bronchiolitis obliterans syndrome after lung transplantation. 54 61
15477118 2004
10
Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. 54 61
15454171 2004
11
Heme-oxygenase-1 expression correlates with severity of acute cellular rejection in lung transplantation. 54 61
15194077 2004
12
Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. 54 61
15135367 2004
13
Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. 54 61
14585390 2003
14
Graft protective effects of heme oxygenase 1 in mouse tracheal transplant-related obliterative bronchiolitis. 54 61
12973103 2003
15
Increased expression of heme oxygenase-1 in human lung transplantation. 54 61
12398878 2002
16
Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. 61 54
11981419 2002
17
The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. 54 61
11493399 2001
18
Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. 61 54
11337368 2001
19
Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. 61 54
11112142 2000
20
Clotrimazole inhibits lung fibroblast proliferation in vitro: implications for use in the prevention and treatment of obliterative bronchiolitis after lung transplantation. 61 54
11063355 2000
21
Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. 61 54
10933164 2000
22
On interleukin-8, neutrophil activation, and bronchiolitis obliterans syndrome in lung transplantation. 61 54
10933146 2000
23
Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 61 54
10798763 2000
24
Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. 61 54
10528744 1999
25
Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. 54 61
8892657 1996
26
The role of cytokines in human lung fibrosis. 61 54
8680382 1996
27
Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. 61
32369682 2020
28
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome. 61
32324952 2020
29
Increased Acid Exposure on Pretransplant Impedance-pH Testing Is Associated With Chronic Rejection After Lung Transplantation. 61
32091450 2020
30
Sauropus androgynus L. Merr.-A phytochemical, pharmacological and toxicological review. 61
32205260 2020
31
Noninvasive methods for detection of chronic lung allograft dysfunction in lung transplantation. 61
32498976 2020
32
[Predictors for the Bronchiolitis Obliterans Syndrome in Lung Transplant Patient]. 61
32517455 2020
33
Health-related quality of life in patients with bronchiolitis obliterans. 61
32515559 2020
34
Bronchoalveolar lavage T cell cytokine profiles and their association with lung function in children with Mycoplasma pneumoniae -associated bronchiolitis obliterans. 61
32478954 2020
35
Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice. 61
32108749 2020
36
PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation. 61
32541091 2020
37
Postinfectious bronchiolitis obliterans and asthma: A misdiagnosis or overlap? 61
32558364 2020
38
Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease. 61
31484991 2020
39
Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?-a case report. 61
31755131 2020
40
Retrospective analysis of 45 cases of localized retroperitoneal Castleman disease from a single center. 61
32509816 2020
41
Azithromycin Partially Mitigates Dysregulated Repair of Lung Allograft Small Airway Epithelium. 61
31985728 2020
42
LPS-induced Airway-centered Inflammation Leading to BOS-like Airway Remodeling Distinct From RAS-like Fibrosis in Rat Lung Transplantation. 61
31929420 2020
43
Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. 61
31821885 2020
44
VEGF synthesis and VEGF receptor 2 expression in patients with bronchiolitis obliterans syndrome after lung transplantation. 61
32250877 2020
45
Clinical and imaging characteristics of hematologic disease complicated by air leak syndrome: A STROBE-compliment observational study. 61
32443296 2020
46
Primary immunodeficiency disorders in children with Non-Cystic Fibrosis Bronchiectasis. 61
32372587 2020
47
Post-Breast Cancer Radiotherapy Bronchiolitis Obliterans Organizing Pneumonia. 61
31892515 2020
48
Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report. 61
32444124 2020
49
Acute respiratory failure among lung transplant adults requiring intensive care: Changing spectrum of causative organisms and impact of procalcitonin test in the diagnostic workup. 61
32473604 2020
50
Imaging Evaluation of Airway Complications After Lung Transplant. 61
32176159 2020

Variations for Bronchiolitis Obliterans

Expression for Bronchiolitis Obliterans

Search GEO for disease gene expression data for Bronchiolitis Obliterans.

Pathways for Bronchiolitis Obliterans

Pathways related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF TIMP1 SLPI PPL PDGFB MPO
2
Show member pathways
13.85 TNF TIMP1 PDGFB IL6 IL17A IL13
3
Show member pathways
13.72 TNF TIMP1 IL6 IL17A IL13 IL10
4
Show member pathways
13.59 TNF TIMP1 PDGFB IL6 IL17A IL13
5
Show member pathways
13.46 TNF TIMP1 PDGFB IL6 IL17A IL13
6
Show member pathways
13.38 TNF TIMP1 PDGFB MMP9 IL6 IL17A
7
Show member pathways
13.35 TNF TIMP1 PDGFB IL6 IL17A IL13
8
Show member pathways
13.12 TNF SFTPD MMP9 IL6 IL10 IFNG
9 12.9 PDGFB MMP9 IL6 IL13 IFNG CXCL8
10
Show member pathways
12.87 TNF IL6 IL17A IL13 IL10 IFNG
11
Show member pathways
12.65 TNF IL6 IL17A IL10 IFNG
12
Show member pathways
12.64 TNF IL6 IL17A IL13 IL10 IFNG
13 12.63 TNF MPO IL17A IL10 IFNG FOXP3
14
Show member pathways
12.57 TNF TIMP1 PDGFB MPO IL6 IL17A
15
Show member pathways
12.5 PDGFB IL6 IL13 IL10 IFNG
16
Show member pathways
12.4 TNF IL6 IL10 CXCR3 CXCL8
17
Show member pathways
12.4 TNF MPO IL6 IFNG CRP
18
Show member pathways
12.34 TNF MMP9 IL6 IL17A IL13 IFNG
19 12.31 MPO MMP9 IL6 CXCL8
20 12.27 TNF IL6 IL10 IFNG
21
Show member pathways
12.26 TNF SFTPD IL6 IFNG CXCL8
22 12.25 TNF IL6 IL13 IL10 CXCL8
23 12.23 TNF MMP9 IL6 IFNG
24 12.15 TNF PDGFB MMP9 IFNG
25 12.09 TNF MMP9 IL6 IFNG CXCL8
26 12.07 TNF IL6 IL10 CXCL8
27 12.07 TNF MPO IL6 IL10 IFNG
28
Show member pathways
12.02 TNF TIMP1 PDGFB IL6 IL17A IL13
29
Show member pathways
12.01 TNF IL6 IL17A IL10 IFNG
30 11.99 TNF IL6 IL10 IFNG CXCL8
31
Show member pathways
11.98 TNF TIMP1 MMP9 MMP8
32
Show member pathways
11.95 IL6 IL17A FOXP3 CXCL8
33 11.93 TNF IL6 IL17A IFNG CXCL8
34 11.88 IL6 IL13 IFNG CXCL8
35 11.84 TNF IL6 IL10 CXCL8
36
Show member pathways
11.84 TNF IFNG FOXP3 CXCL8
37 11.82 TNF IL6 IL10 IFNG
38 11.75 TNF IL17A IL13 IL10 IFNG CXCR3
39 11.72 MMP9 IL6 CXCL8
40
Show member pathways
11.69 TNF MMP9 IL6 IFNG CXCL8
41 11.68 TIMP1 MMP9 CXCL8
42 11.65 TNF IL6 CXCL8
43 11.63 IL6 IFNG CXCL8
44 11.61 TNF MPO MMP9 IL6
45 11.6 TNF IL6 IFNG
46 11.59 IL13 IL10 IFNG FOXP3
47 11.57 TNF IL6 IL10 IFNG CXCL8
48 11.54 TNF IL6 IFNG
49 11.47 TNF IL6 IL10 IFNG
50
Show member pathways
11.46 TNF IL10 IFNG FOXP3

GO Terms for Bronchiolitis Obliterans

Cellular components related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF TIMP1 SLPI SFTPD SCGB1A1 PDGFB
2 extracellular space GO:0005615 9.53 TNF TIMP1 SLPI SFTPD SCGB1A1 PDGFB

Biological processes related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.04 TNF PDGFB MMP8 IFNG FOXP3
2 defense response to bacterium GO:0042742 9.99 TNF SLPI SFTPD MPO IL10
3 cellular response to lipopolysaccharide GO:0071222 9.98 TNF IL6 IL10 CXCL8
4 response to lipopolysaccharide GO:0032496 9.91 SLPI SCGB1A1 MPO IL13 IL10
5 extracellular matrix disassembly GO:0022617 9.87 TIMP1 MMP9 MMP8
6 response to mechanical stimulus GO:0009612 9.87 PPL MPO IL13
7 humoral immune response GO:0006959 9.86 TNF IL6 IFNG
8 positive regulation of interleukin-6 production GO:0032755 9.86 TNF MMP8 IL6
9 response to organic substance GO:0010033 9.85 TNF TIMP1 SCGB1A1 IL10
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF IL6 IL13 IFNG
11 positive regulation of phagocytosis GO:0050766 9.83 TNF SFTPD IFNG
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF MMP8 IFNG
13 positive regulation of interleukin-6 secretion GO:2000778 9.83 TNF IL17A IFNG
14 response to glucocorticoid GO:0051384 9.83 TNF SCGB1A1 IL6 IL10
15 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.82 TNF PDGFB IL10
16 negative regulation of interleukin-6 production GO:0032715 9.81 TNF IL10 FOXP3
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 TNF PDGFB IL6 IL13
18 inflammatory response GO:0006954 9.8 TNF IL6 IL17A IL13 CXCR3 CXCL8
19 positive regulation of cytokine secretion GO:0050715 9.79 TNF IL10 IFNG
20 positive regulation of JAK-STAT cascade GO:0046427 9.79 TNF IL6 IL10
21 negative regulation of interferon-gamma production GO:0032689 9.78 SCGB1A1 IL10 FOXP3
22 microglial cell activation GO:0001774 9.77 TNF IL13 IFNG
23 positive regulation of gene expression GO:0010628 9.76 TNF PDGFB MMP8 IL6 IL13 IFNG
24 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.74 TNF IL6 IL17A
25 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL17A IFNG
26 response to molecule of bacterial origin GO:0002237 9.71 IL10 CXCL8
27 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 TNF PDGFB MMP9 IL10
28 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL10 IFNG
30 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
31 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.7 TIMP1 IL10
32 negative regulation of cytokine production involved in immune response GO:0002719 9.68 TNF IL10
33 negative regulation of interleukin-2 biosynthetic process GO:0045085 9.68 SFTPD FOXP3
34 positive regulation of interleukin-23 production GO:0032747 9.67 IL17A IFNG
35 negative regulation of interleukin-5 production GO:0032714 9.67 SCGB1A1 FOXP3
36 negative regulation of interleukin-4 production GO:0032713 9.67 SCGB1A1 FOXP3
37 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 TNF IL10
38 regulation of microglial cell activation GO:1903978 9.65 MMP8 IL6
39 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF MMP8 IL6
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 TNF IFNG
41 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 MMP8 IL6
42 receptor biosynthetic process GO:0032800 9.62 TNF IL10
43 negative regulation of T cell proliferation GO:0042130 9.62 SFTPD SCGB1A1 IL10 FOXP3
44 negative regulation of lipid storage GO:0010888 9.61 TNF IL6 CRP
45 immune response GO:0006955 9.61 TNF SLPI IL6 IL17A IL13 IL10
46 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
47 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
48 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.54 TNF IL17A IFNG
49 cytokine-mediated signaling pathway GO:0019221 9.23 TNF TIMP1 MMP9 IL6 IL17A IL13

Molecular functions related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNF TIMP1 SLPI SFTPD SCGB1A1 PPL
2 growth factor activity GO:0008083 9.46 TIMP1 PDGFB IL6 IL10
3 cytokine activity GO:0005125 9.23 TNF TIMP1 IL6 IL17A IL13 IL10

Sources for Bronchiolitis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....